Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two new appointments at Biovail

This article was originally published in Scrip

Executive Summary

Biovail (Canada) has appointed Peggy Mulligan chief financial officer and Dr Neil Sussman vice-president of neurologic and psychiatric development at Biovail Technologies. Mrs Mulligan succeeds Adrian De Saldanha, who had been serving as Biovail's interim chief financial officer; she most recently served as a principal at Priiva Consulting. Dr Sussman was previously president of NMSNeuro Consulting, specialising in therapeutic areas such as dementia, mania, neuroprotection, multiple sclerosis and Parkinson's disease. Before that, he was senior director of CNS clinical research at Kyowa Pharmaceutical.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts